Inventor · disambiguated record
Alain D. Baron
Also filed as: BARON ALAIN · BARON ALAIN D
34 granted patents·18 pending applications·355 citations·filing 2003–2024
97Inventor score
Files withELCELYX THERAPEUTICS INC11BARON ALAIN D9AMYLIN PHARMACEUTICALS INC5ANJI PHARMA US LLC4BARON ALAIN4
Top patents by PatentIndex Score
52 records- 0197US9211263B2Compositions and methods of treating metabolic disordersELCELYX THERAPEUTICS INC·Filed 2013·Granted Dec 15, 2015·24 cites·8 claims
- 0296US10610500B2Chemosensory receptor ligand-based therapiesANJI PHARMA US LLC·Filed 2018·Granted Apr 7, 2020·8 cites·41 claims
- 0396US8263545B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Sep 11, 2012·62 cites·3 claims
- 0495US10028923B2Biguanide compositions and methods of treating metabolic disordersELCELYX THERAPEUTICS INC·Filed 2016·Granted Jul 24, 2018·9 cites·26 claims
- 0595US9962344B2Chemosensory receptor ligand-based therapiesELCELYX THERAPEUTICS INC·Filed 2016·Granted May 8, 2018·14 cites·24 claims
- 0695US9481642B2Biguanide compositions and methods of treating metabolic disordersELCELYX THERAPEUTICS INC·Filed 2014·Granted Nov 1, 2016·14 cites·25 claims
- 0795US9463170B2Chemosensory receptor ligand-based therapiesELCELYX THERAPEUTICS INC·Filed 2015·Granted Oct 11, 2016·15 cites·35 claims
- 0895US8796338B2Biguanide compositions and methods of treating metabolic disordersBARON ALAIN D·Filed 2012·Granted Aug 5, 2014·27 cites·14 claims
- 0995US8497240B2DPP-IV resistant GIP hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Jul 30, 2013·25 cites·11 claims
- 1094US10159658B2Compositions comprising statins, biguanides and further agents for reducing cardiometabolic riskELCELYX THERAPEUTICS INC·Filed 2017·Granted Dec 25, 2018·8 cites·29 claims
- 1194US9770422B2Compositions and methods for treating metabolic disordersELCELYX THERAPEUTICS INC·Filed 2015·Granted Sep 26, 2017·7 cites·23 claims
- 1293US10603291B2Compositions and methods for treating metabolic disordersANJI PHARMA US LLC·Filed 2017·Granted Mar 31, 2020·5 cites·30 claims
- 1393US9050292B2Chemosensory receptor ligand-based therapiesBARON ALAIN D·Filed 2012·Granted Jun 9, 2015·24 cites·25 claims
- 1492US10668031B2Biguanide compositions and methods of treating metabolic disordersANJI PHARMA US LLC·Filed 2018·Granted Jun 2, 2020·6 cites·24 claims
- 1592US10154972B2Biguanide compositions and methods of treating metabolic disordersELCELYX THERAPEUTICS INC·Filed 2016·Granted Dec 18, 2018·10 cites·27 claims
- 1692US9572784B2Compositions comprising statins, biguanides and further agents for reducing cardiometabolic riskELCELYX THERAPEUTICS INC·Filed 2013·Granted Feb 21, 2017·7 cites·23 claims
- 1792US8389473B2Treatment of cardiac arrhythmiasHATHAWAY DAVID R·Filed 2010·Granted Mar 5, 2013·14 cites·17 claims
- 1891US9480663B2Biguanide compositions and methods of treating metabolic disordersBARON ALAIN D·Filed 2012·Granted Nov 1, 2016·8 cites·27 claims
- 1990US8404637B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2006·Granted Mar 26, 2013·16 cites·12 claims
- 2088US10201511B2Compositions and methods for treating metabolic disordersELCELYX THERAPEUTICS INC·Filed 2013·Granted Feb 12, 2019·8 cites·39 claims
- 2188US8828953B2Chemosensory receptor ligand-based therapiesBARON ALAIN·Filed 2010·Granted Sep 9, 2014·8 cites·22 claims
- 2288US7790681B2Treatment of cardiac arrhythmias with GLP-1 receptor ligandsAMYLIN PHARMACEUTICALS INC·Filed 2003·Granted Sep 7, 2010·17 cites·14 claims
- 2383US11065215B2Biguanide compositions and methods of treating metabolic disordersANJI PHARMA US LLC·Filed 2018·Granted Jul 20, 2021·3 cites·23 claims
- 2482US8394765B2Methods of treating obesity with two different anti-obesity agentsROTH JONATHAN D·Filed 2007·Granted Mar 12, 2013·5 cites·33 claims
- 2580US8389472B2Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver diseaseBARON ALAIN D·Filed 2006·Granted Mar 5, 2013·5 cites·16 claims
- 2677US2025000804A1Compositions and methods for treating metabolic disordersANJI PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2776US9526741B2Chemosensory receptor ligand-based therapiesNAZURA BIOHEALTH INC·Filed 2014·Granted Dec 27, 2016·2 cites·18 claims
- 2870US9133260B2GIP analog and hybrid polypeptides with selectable propertiesAMYLIN PHARMACEUTICALS LLC·Filed 2013·Granted Sep 15, 2015·1 cites·8 claims
- 2969US2009203603A1Compositions for the Treatment and Prevention of NephropathyAMYLIN PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3067US9486463B2Chemosensory receptor ligand-based therapiesBARON ALAIN D·Filed 2011·Granted Nov 8, 2016·1 cites·33 claims
- 3166US2013209586A1Prevention And Treatment Of Cardiac ArrhythmiasAMYLIN PHARMACEUTICALS LLC·Filed 2013·Application pending·0 cites
- 3265US9901551B2Chemosensory receptor ligand-based therapiesBARON ALAIN·Filed 2010·Granted Feb 27, 2018·1 cites·16 claims
- 3365US9114560B2Blowing device comprising a nozzle and a supply duct forming an obtuse angleBARON ALAIN·Filed 2012·Granted Aug 25, 2015·1 cites·20 claims
- 3464US2014200183A1Treatment of cardiac arrhythmiasASTRAZENECA PHARMACEUTICALS LP·Filed 2014·Application pending·0 cites
- 3558US11759441B2Biguanide compositions and methods of treating metabolic disordersANJI PHARMACEUTICALS INC·Filed 2021·Granted Sep 19, 2023·0 cites·13 claims
- 3657US2020093750A1Compositions and methods for treating metabolic disordersBARON ALAIN D·Filed 2019·Application pending·0 cites
- 3757US2004209803A1Compositions for the treatment and prevention of nephropathyBARON ALAIN·Filed 2003·Application pending·0 cites
- 3855US8895498B2GIP and exendin hybrid polypeptidesLEVY ODILE ESTHER·Filed 2012·Granted Nov 25, 2014·0 cites·6 claims
- 3955US2007021336A1Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosisANDERSON CHRISTEN·Filed 2005·Application pending·0 cites
- 4054US2009264352A1Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosisANDERSON CHRISTEN·Filed 2009·Application pending·0 cites
- 4154US2014193498A1Compositions and Methods for Treating Metabolic DisordersELCELYX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4252US11974971B2Compositions and methods for treating metabolic disordersANJI PHARMACEUTICALS INC·Filed 2019·Granted May 7, 2024·0 cites·7 claims
- 4349US12450723B2System and method for identifying geometric feature associations for 3D modelsPRATT & WHITNEY CANADA·Filed 2022·Granted Oct 21, 2025·0 cites·19 claims
- 4448US2007275877A1Methods for Treating or Ameliorating Ghrelin-Associated Diseases and DisordersAMYLIN PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 4548US2013281374A1Dpp-iv resistant gip hybrid polypeptides with selectable propertiesASTRAZENECA PHARMACEUTICALS LP·Filed 2013·Application pending·0 cites
- 4647US2025328696A1Model-based definition manufacturing and inspection system including data modelPRATT & WHITNEY CANADA·Filed 2024·Application pending·0 cites
- 4747US2010323955A1Methods for treating obesity and obesity related diseases and disordersAMYLIN PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 4842US2009156474A1Methods for treating obesity and obesity related diseases and disordersAMYLIN PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 4937US2013281387A1Chemosensory Receptor Ligand-Based TherapiesBARON ALAIN D·Filed 2011·Application pending·0 cites
- 5037US2013303466A1Chemosensory Receptor Ligand-Based TherapiesBROWN MARTIN R·Filed 2011·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →